Alessandra Blasina

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
    Alessandra Blasina
    Department of Cancer Biology, Pfizer Global Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA
    Mol Cancer Ther 7:2394-404. 2008
  2. doi request reprint PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
    Jing Yuan
    Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Mol Cancer Ther 10:2189-99. 2011
  3. ncbi request reprint Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors
    Min Teng
    Department of Medicinal Chemistry, Pfizer Global Research and Development, La Jolla, Inc, 10770 Science Center Drive, San Diego, California 92121 1194, USA
    J Med Chem 50:5253-6. 2007
  4. doi request reprint Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line
    Douglas D Fang
    Oncology Research Unit, Pfizer, Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA
    Front Med 7:462-76. 2013

Collaborators

  • Ping Chen
  • Stephan Grant
  • Hengmiao Cheng
  • Zhengwei Peng
  • Min Teng
  • Min Jean Yin
  • Karen Lundgren
  • Douglas D Fang
  • Jing Yuan
  • Jianying Wang
  • Justin Bingham
  • Todd Vanarsdale
  • Jitesh P Jani
  • Zuzana Jirout
  • Gerrit Los
  • Yin Gu
  • Zhou Zhu
  • Joan Cao
  • Maruja E Lira
  • Zdenek Hostomsky
  • Jill Kornmann
  • Konstantinos Tsaparikos
  • Minghao Sun
  • Jill Hallin
  • Jeffrey Nickel
  • Shaoxian Sun
  • Eric Zhang
  • Peter K Vogt
  • Jon Engebretsen
  • Julie L C Kan
  • Aileen McHarg
  • Aihua Zou
  • Zheng Feng
  • Jeffrey Chen
  • James G Christensen
  • Pramod P Mehta
  • Kristina Rafidi
  • Shubha Bagrodia
  • Leslie Nguyen

Detail Information

Publications4

  1. doi request reprint Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
    Alessandra Blasina
    Department of Cancer Biology, Pfizer Global Research and Development, 10724 Science Center Drive, San Diego, CA 92121, USA
    Mol Cancer Ther 7:2394-404. 2008
    ..In xenografts, PF-00477736 enhanced the antitumor activity of gemcitabine in a dose-dependent manner. PF-00477736 combinations were well tolerated with no exacerbation of side effects commonly associated with cytotoxic agents...
  2. doi request reprint PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
    Jing Yuan
    Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Mol Cancer Ther 10:2189-99. 2011
    ..In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity. PF-04691502 has entered phase I clinical trials...
  3. ncbi request reprint Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors
    Min Teng
    Department of Medicinal Chemistry, Pfizer Global Research and Development, La Jolla, Inc, 10770 Science Center Drive, San Diego, California 92121 1194, USA
    J Med Chem 50:5253-6. 2007
    ..Compound 10c, showing no single agent effect, potentiated the antiproliferative effect of Gemcitabine in both prostate and breast cancer cell lines...
  4. doi request reprint Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line
    Douglas D Fang
    Oncology Research Unit, Pfizer, Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA
    Front Med 7:462-76. 2013
    ....